Resources
AVAC’s Resource Database contains educational and advocacy materials covering a wide range of issues on biomedical prevention of HIV, STIs, COVID-19 and emerging health threats—from research to rollout.
To search for clinical trials and detailed information on products in development, visit our Prevention Research & Development Database
Results
showing 1-10 of 261
Cabotegravir Volume
Allocation of non-commercial cabotegravir for PrEP supply in low- and middle-income countries, 2023-2026, as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on...
Prevention Option:

Dapivirine Vaginal Ring Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:

Cabotegravir Regulatory Approval
Regulatory approvals and those pending for cabotegravir as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:

Dapivirine Vaginal Ring Volume
DVR supply available to low- and middle-income countries as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:

Dapivirine Vaginal Ring Implementation
Ongoing and planned implementation studies for the dapivirine vaginal ring as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:

Cabotegravir Implementation
Implementation studies completed, ongoing, or planned for cabotegravir as of December 2024. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:

PrEP Price Comparison
Comparing the annual price of oral TDF/FTC vs. the dapivirine vaginal ring and injectable cabotegravir. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Prevention Option:

The Gears Framework for Lenacapavir for PrEP Rollout
The gears framework for lenacapavir scale-up brings together a coalition of essential stakeholders, each contributing to the successful, sustainable integration of this HIV prevention tool into global health systems.
Prevention Option:

Gears of Lenacapavir for PrEP Rollout
This document outlines a focused plan for LEN for PrEP rollout over the next few years, specifying priorities by stakeholder and evaluating volume and pricing strategies. The report as a whole details a coordinated response to this historic opportunity to ensure rapid implementation, equitable access, and sustainable impact.
Prevention Option:

Oral PrEP Prices in LMICs
This chart tracks pricing for oral PrEP as tenofovir disoproxil and emtricitabine (TDF/FTC) as compared to generic pricing in low- and middle-income countries (LMICs) since 2005.
Prevention Option:

showing 1-10 of 261